To include your compound in the COVID-19 Resource Center, submit it here.

Ligand's LGD-6972 meets in Phase II for Type II diabetes

In September, Ligand Pharmaceuticals Inc. (NASDAQ:LGND) reported top-line data from a Phase II trial in 166 patients with

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE